查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1702634

全球心臟生物植入设备市场、市场规模和占有率分析－成长趋势和预测（2025-2033）

Global Cardiac Bio Implant Devices Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033
出版日期: | 出版商: Renub Research | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球心臟生物植入设备市场规模预计将从 2024 年的 397.6 亿美元成长到 2033 年的 741 亿美元，2025 年至 2033 年的复合年增长率为 7.16%。由于人口老化、患者意识增强、对微创治疗方案的需求不断增长、心血管疾病患病率上升以及植入技术的进步等因素，市场正在扩大。

推动心臟生物植入设备市场成长的因素

微创手术

由于人口老化、不良的生活习惯和遗传因素，心血管疾病变得越来越普遍，这推动了心臟生物植入设备市场的成长。植入材料和设计技术的进步已经改善了患者的治疗效果、提高了设备的耐用性和效率。良好的医疗保健基础设施、不断增长的患者知识以及微创手术的广泛采用进一步推动了需求。强有力的报销和监管框架以及全球不断上涨的医疗保健成本正在推动心臟生物植入物市场的成长。

心血管疾病盛行率不断上升

推动心臟生物植入物市场扩张的关键因素是心血管疾病盛行率的上升。随着冠状动脉疾病等心臟病变得越来越普遍，对心臟瓣膜、起搏器和支架的需求也不断增长。大约有 2,010 万名 20 岁以上的美国人患有冠心病，根据美国疾病管制与预防中心的数据，每 40 秒就会发生一次心臟病发作，每年有 805,000 人患有心臟病。人口老化和心臟病盛行率上升可能会增加对生物植入物的需求。随着慢性心血管疾病变得越来越普遍，用于治疗慢性心血管疾病的复杂生物植入物的需求只会增加，从而推动市场扩张。为了解决日益加重的健康负担，必须转向使用更持久、更有效的植入物。

技术进步

心臟生物植入物市场的主要驱动力之一是技术进步。材料、设计和製造技术的进步正在生产出更坚固、更有效和生物相容性更好的植入物。近年来，心臟瓣膜、起搏器和支架等生物医学植入物变得更加精确、更小，并且针对每个患者进行定制，从而改善了治疗效果并降低了风险。 3D 列印、智慧技术和微创手术技术的发展进一步促进了这些设备的使用。这些发展透过改善治疗效果和扩大适合心臟生物植入物的患者群体来推动市场扩张。

心臟生物植入设备市场的课题

成本高

高价位是心臟生物植入物市场的一个主要障碍。生物植入设备成本高昂，这是因为其製造过程中采用了先进的技术、材料和製造技术，并且需要专门的手术技术。这可能会限制患者的就医机会，尤其是在低收入地区和医疗保健系统欠发达的国家。此外，过高的成本可能会给保险公司和医疗保健提供者带来负担，并阻碍救生心臟植入物在某些市场的广泛使用。

监理障碍

心臟生物植入设备领域面临的最大障碍之一是监管障碍。新技术的监管程序可能漫长而具有课题性，从而延迟市场推出并减缓创新和获得尖端治疗的机会。虽然有必要，但监管机构严格的安全性和有效性标准增加了开发新产品所需的时间和费用。小型製造商和新技术可能会特别受到这些问题的影响，这可能会减少竞争并延迟向有需要的患者及时提供有益的心臟生物植入物。

本报告研究了全球心臟生物植入设备市场，并提供了成长动力和课题、每个细分市场的分析以及关键参与者。

目录

第1章简介

第2章 研究方法

第 3 章执行摘要

第4章 市场动态

  • 成长动力
  • 课题

第5章 全球心臟生物植入设备市场

第6章市占率分析

  • 依类型
  • 依用途
  • 由最终用户
  • 依国家/地区

第 7 章 类型

  • 心律调节器
  • ICD（植入式心臟復律去颤器）
  • CRT（心臟再同步治疗）

第 8 章用途

  • 心律不整
  • 心肌缺血
  • 急性心肌梗塞
  • 心臟衰竭

第 9 章 最终使用者

  • 医院
  • 门诊手术中心
  • 心导管室
  • 其他

第10章 国

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 比利时
    • 荷兰
    • 土耳其
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 泰国
    • 马来西亚
    • 印尼
    • 澳大利亚
    • 纽西兰
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 南非
  • 其他地区

第 11 章 波特五力分析

第 12 章 SWOT 分析

第13章主要公司分析

  • F. Hoffman-La Roche
  • Eurofins Scientific
  • Illumina, Inc.
  • Natera Inc.
  • Abbott Laboratories
  • Thermo Fisher Scientific
  • Quest Diagnostics
  • Agilent Technologies
简介目录

Global Cardiac Bio Implant Devices Market Trends & Summary

Cardiac Bio Implant Devices Market is expected to reach US$ 74.10 billion in 2033 from US$ 39.76 billion in 2024, with a CAGR of 7.16% from 2025 to 2033. The market for cardiac bioimplants is expanding due to factors such as aging populations, improved patient awareness, growing demand for minimally invasive treatment choices, rising prevalence of cardiovascular disease, and developments in implant technology.

Cardiac Bio Implant Market Global Report by Type (Pacemaker, ICDs (Implantable Cardioverter Defibrillator), CRT (Cardiac Resynchronization Therapy)), Application (Arrhythmias, Myocardial Ischemia, Acute Myocardial Infarction, Heart Failure), End-User (Hospitals, Ambulatory Surgical Centers, Cardiac Catheterization Laboratories, Others), Countries and Company Analysis 2025-2033.

Cardiac Bio Implant Devices Industry Overview

Patients with cardiovascular disorders can benefit from cardiac bioimplants, which are medical devices that replace or support damaged heart components. These implants consist of artificial cardiac pumps, pacemakers, stents, and heart valves. The danger of rejection is reduced by the smooth integration of cardiac bioimplants, which are made of biocompatible materials. Usually, they are used to treat heart failure, arrhythmias, and aortic stenosis. Technological developments have made cardiac bioimplants more effective, long-lasting, and minimally invasive, improving patient outcomes, shortening recovery periods, and providing a better way to treat complicated cardiac disorders.

Due to aging populations, poor lifestyles, and genetic factors, cardiovascular problems are becoming more common, which is driving growth in the cardiac bioimplant devices market. Patient outcomes, device durability, and efficiency have all improved as a result of technological developments in implant materials and designs. Better healthcare infrastructure, increased patient knowledge, and the growing use of minimally invasive procedures are further driving demand. Strong reimbursement and regulatory frameworks, as well as rising healthcare costs worldwide, are all driving the cardiac bioimplant devices market's growth.

Growth Drivers for the Cardiac Bio Implant Devices Market

Minimally Invasive Procedures

Due to aging populations, poor lifestyles, and genetic factors, cardiovascular problems are becoming more common, which is driving growth in the cardiac bioimplant devices market. Patient outcomes, device durability, and efficiency have all improved as a result of technological developments in implant materials and designs. Better healthcare infrastructure, increased patient knowledge, and the growing use of minimally invasive procedures are further driving demand. Strong reimbursement and regulatory frameworks, as well as rising healthcare costs worldwide, are all driving the cardiac bioimplant devices market's growth.

Rising Cardiovascular Disease Prevalence

An important factor propelling the cardiac bioimplant devices market's expansion is the rising incidence of cardiovascular illness. The need for heart valves, pacemakers, and stents is increasing as cardiac diseases, such as coronary artery disease, become increasingly common. About 20.1 million persons in the United States who are 20 years of age or older suffer from coronary heart disease, with one heart attack every 40 seconds, or 805,000 each year, according to the Centers for Disease Control and Prevention. The need for bioimplants will increase as a result of the aging population and the rising prevalence of cardiac disease. The need for sophisticated bioimplants to treat chronic cardiovascular illnesses will only increase as these ailments become more prevalent, propelling market expansion. To address this increasing health burden, a move toward implants that are more permanent and effective will be essential.

Technological Advancements

One of the main factors propelling the market for cardiac bioimplants devices is technological advances. More robust, effective, and biocompatible implants have been created as a result of advancements in materials, design, and manufacturing techniques. These days, bioimplants-like cardiac valves, pacemakers, and stents-are more accurate, smaller, and customized for each patient, which enhances results and lowers risks. The use of these devices has been further boosted by developments in 3D printing, smart technology, and minimally invasive surgical methods. These developments are driving market expansion by improving treatment efficacy and broadening the patient base suitable for cardiac bioimplants.

Challenges in the Cardiac Bio Implant Devices Market

High costs

The market for cardiac bioimplants devices is severely hampered by high prices. The high cost of bioimplant devices is a result of the sophisticated technology, materials, and manufacturing techniques used in their creation as well as the specific surgical techniques needed. Patients' access may be restricted as a result, especially in low-income areas or nations with less developed healthcare systems. Furthermore, exorbitant expenses may put a strain on insurers and healthcare providers, preventing the broad use of life-saving cardiac bioimplants in some markets.

Regulatory Hurdles

One of the biggest obstacles facing the cardiac bioimplant devices sector is regulatory barriers. Innovation and access to cutting-edge therapies may be slowed by the drawn-out and difficult regulatory procedures for new technologies, which can postpone market introduction. Although necessary, regulatory agencies' strict safety and efficacy standards lengthen the time and expense needed to develop new products. Smaller manufacturers or emerging technologies may be especially impacted by these issues, which could reduce competition and delay the timely delivery of beneficial cardiac bioimplants to patients in need.

Cardiac Bio Implant Devices Market Overview by Regions

The market for cardiac bioimplant devices is expanding significantly on a regional basis. Because of its strong research, large prevalence of cardiovascular illnesses, and sophisticated healthcare infrastructures, North America leads the world. Europe is next, where aging populations and new technology are driving up demand. The Asia Pacific region is expanding quickly due to improved medical infrastructure, increased disease rates, and easier access to healthcare. As healthcare investments rise in Latin America and the Middle East, these regions are also growing.

United States Cardiac Bio Implant Devices Market

Due to the high frequency of cardiovascular disorders, such as heart failure and coronary heart disease, the US cardiac bioimplant market is a major global leader. Technological developments in bioimplant devices, such as heart valves, pacemakers, and stents, as well as a strong healthcare system, help the market. Impulse Dynamics approved and introduced the Optimizer Smart Mini Implantable Pulse Generator (IPG) in the United States in April 2022. By treating moderate to severe heart failure, this Class III medical device gives patients even more therapy alternatives.

The demand for cardiac bioimplants is rising due to a number of factors, including an aging population, an increase in illness rates, and growing patient awareness. Furthermore, the U.S. market is growing and innovating due to advantageous reimbursement rules, better medical infrastructure, and continuous research.

Germany Cardiac Bio Implant Devices Market

Due to a strong healthcare system and a high prevalence of cardiovascular illnesses, Germany has one of the biggest cardiac bioimplant markets in Europe. The market for pacemakers, stents, and cardiac valves is growing as a result of an aging population and rising demand for cutting-edge therapies. The adoption of novel bioimplant technologies is facilitated by Germany's emphasis on medical innovation and research as well as its advantageous reimbursement regulations. Continuous improvements in implant materials and design support expansion and enhance patient outcomes nationwide.

India Cardiac Bio Implant Devices Market

The market for cardiac bioimplants is expanding quickly in India because to the rising incidence of cardiovascular diseases (CVDs), which rank among the nation's top causes of mortality. The World Health Organization reports that more than 27% of deaths in India are caused by CVDs. The adoption of cutting-edge medical technologies, increased awareness of cardiac disease, and better healthcare infrastructure all help the industry. Because of government healthcare programs and cost reductions, bioimplants such as heart valves, pacemakers, and stents are becoming more widely available. In the upcoming years, there will likely be a significant increase in demand for cardiac bioimplants due to the growing middle class and the growing medical tourism industry.

Saudi Arabia Cardiac Bio Implant Devices Market

The market for cardiac bioimplants in Saudi Arabia is expanding quickly due to the country's high rate of cardiovascular disorders, which are a major cause of death. The need for sophisticated therapies like pacemakers, stents, and cardiac valves is growing as the population ages and the number of lifestyle-related illnesses rises. The market is expanding as a result of government investments in healthcare infrastructure and advancements in medical technology. Additionally, the use of cardiac bioimplants is accelerating throughout Saudi Arabia owing to an emphasis on patient knowledge and healthcare accessibility.

Global Cardiac Bio Implant Device Market Segments

Type

1. Pacemaker

2. ICDs (Implantable Cardioverter Defibrillator)

3. CRT (Cardiac Resynchronization Therapy)

Application

1. Arrhythmias

2. Myocardial Ischemia

3. Acute Myocardial Infarction

4. Heart Failure

End-User

1. Hospitals

2. Ambulatory Surgical Centers

3. Cardiac Catheterization Laboratories

4. Others

Countries

North America

1. United States

2. Canada

Europe

1. France

2. Germany

3. Italy

4. Spain

5. United Kingdom

6. Belgium

7. Netherlands

8. Turkey

Asia Pacific

1. China

2. Japan

3. India

4. South Korea

5. Thailand

6. Malaysia

7. Indonesia

8. Australia

9. New Zealand

Latin America

1. Brazil

2. Mexico

3. Argentina

Middle East & Africa

1. Saudi Arabia

2. UAE

3. South Africa

Rest of the World

All the Key players have been covered from 5 Viewpoints:

1. Overview

2. Key Persons

3. Product Portfolio

4. Recent Development & Strategies

5. Revenue Analysis

Key Players Analysis

1. F. Hoffman-La Roche

2. Eurofins Scientific

3. Illumina, Inc.

4. Natera Inc.

5. Abbott Laboratories

6. Thermo Fisher Scientific

7. Quest Diagnostics

8. Agilent Technologies

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. Global Cardiac Bio Implant Devices Market

6. Market Share Analysis

  • 6.1 By Type
  • 6.2 By Application
  • 6.3 By End User
  • 6.4 By Countries

7. Type

  • 7.1 Pacemaker
  • 7.2 ICDs (Implantable Cardioverter Defibrillator)
  • 7.3 CRT (Cardiac Resynchronization Therapy)

8. Application

  • 8.1 Arrhythmias
  • 8.2 Myocardial Ischemia
  • 8.3 Acute Myocardial Infarction
  • 8.4 Heart Failure

9. End-User

  • 9.1 Hospitals
  • 9.2 Ambulatory Surgical Centers
  • 9.3 Cardiac Catheterization Laboratories
  • 9.4 Others

10. Countries

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
  • 10.2 Europe
    • 10.2.1 France
    • 10.2.2 Germany
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Belgium
    • 10.2.7 Netherlands
    • 10.2.8 Turkey
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Thailand
    • 10.3.6 Malaysia
    • 10.3.7 Indonesia
    • 10.3.8 Australia
    • 10.3.9 New Zealand
  • 10.4 Latin America
    • 10.4.1 Brazil
    • 10.4.2 Mexico
    • 10.4.3 Argentina
  • 10.5 Middle East & Africa
    • 10.5.1 Saudi Arabia
    • 10.5.2 UAE
    • 10.5.3 South Africa
  • 10.6 Rest of the World

11. Porter's Five Forces Analysis

  • 11.1 Bargaining Power of Buyers
  • 11.2 Bargaining Power of Suppliers
  • 11.3 Degree of Rivalry
  • 11.4 Threat of New Entrants
  • 11.5 Threat of Substitutes

12. SWOT Analysis

  • 12.1 Strength
  • 12.2 Weakness
  • 12.3 Opportunity
  • 12.4 Threat

13. Key Players Analysis

  • 13.1 F. Hoffman-La Roche
    • 13.1.1 Overview
    • 13.1.2 Key Persons
    • 13.1.3 Product Portfolio
    • 13.1.4 Recent Development & Strategies
    • 13.1.5 Revenue Analysis
  • 13.2 Eurofins Scientific
    • 13.2.1 Overview
    • 13.2.2 Key Persons
    • 13.2.3 Product Portfolio
    • 13.2.4 Recent Development & Strategies
    • 13.2.5 Revenue Analysis
  • 13.3 Illumina, Inc.
    • 13.3.1 Overview
    • 13.3.2 Key Persons
    • 13.3.3 Product Portfolio
    • 13.3.4 Recent Development & Strategies
    • 13.3.5 Revenue Analysis
  • 13.4 Natera Inc.
    • 13.4.1 Overview
    • 13.4.2 Key Persons
    • 13.4.3 Product Portfolio
    • 13.4.4 Recent Development & Strategies
    • 13.4.5 Revenue Analysis
  • 13.5 Abbott Laboratories
    • 13.5.1 Overview
    • 13.5.2 Key Persons
    • 13.5.3 Product Portfolio
    • 13.5.4 Recent Development & Strategies
    • 13.5.5 Revenue Analysis
  • 13.6 Thermo Fisher Scientific
    • 13.6.1 Overview
    • 13.6.2 Key Persons
    • 13.6.3 Product Portfolio
    • 13.6.4 Recent Development & Strategies
    • 13.6.5 Revenue Analysis
  • 13.7 Quest Diagnostics
    • 13.7.1 Overview
    • 13.7.2 Key Persons
    • 13.7.3 Product Portfolio
    • 13.7.4 Recent Development & Strategies
    • 13.7.5 Revenue Analysis
  • 13.8 Agilent Technologies
    • 13.8.1 Overview
    • 13.8.2 Key Persons
    • 13.8.3 Product Portfolio
    • 13.8.4 Recent Development & Strategies
    • 13.8.5 Revenue Analysis